Stocktoria
BridgeBio Pharma, Inc. BBIO
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2019-06-27
Chart by TradingView
1/9
Piotroski F — financial health
-14.22
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $502.1M | $221.9M | $9.3M | $77.6M | $69.7M |
| Operating income | -$523.4M | -$593.0M | -$607.4M | -$512.2M | -$576.6M |
| Operating cash flow | -$445.9M | -$520.7M | -$527.7M | -$419.5M | -$497.9M |
| Free cash flow | -$447.0M | -$521.7M | -$529.0M | -$424.3M | -$511.2M |
| Total assets | $936.0M | $919.3M | $546.4M | $623.0M | $1.0B |
| Total liabilities | $3.0B | $2.4B | $1.9B | $1.9B | $1.9B |
| Shareholders' equity | -$2.1B | -$1.5B | -$1.3B | -$1.2B | -$867.0M |
| Ratios | |||||
| Operating margin | -104.2% | -267.2% | -6528.8% | -659.6% | -827.1% |
| FCF margin | -89.0% | -235.1% | -5686.6% | -546.5% | -733.2% |
| Debt / equity | -0.96× | -0.30× | -0.33× | -0.35× | -0.50× |
| Current ratio | 2.77 | 4.67 | 3.32 | 4.52 | 6.58 |
| Revenue growth | 126.3% | 2285.3% | -88.0% | 11.4% | 745.1% |
Notable holders (13F)
| Investor | Shares | Value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | 365,772 | $27.2M |
| Bridgewater Associates, LP | 259,459 | $19.3M |
| Point72 Asset Management, L.P. | 47,200 | $3.5M |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -14.22 (distress)
- Working capital / assets 0.545
- Retained earnings / assets -4.082
- EBIT / assets -0.559
- Equity / liabilities -0.693
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001743881 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.